Home/Filings/4/0000899243-20-014552
4//SEC Filing

Wallace Owen B. 4

Accession 0000899243-20-014552

CIK 0001680581other

Filed

May 28, 8:00 PM ET

Accepted

May 29, 4:15 PM ET

Size

8.8 KB

Accession

0000899243-20-014552

Insider Transaction Report

Form 4
Period: 2020-05-27
Wallace Owen B.
Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2020-05-27$20.00/sh448$8,960127,088 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2020-05-2744887,266 total
    Exercise: $7.84Exp: 2029-01-21Common Stock (448 underlying)
  • Exercise/Conversion

    Common Stock

    2020-05-27$7.84/sh+448$3,512127,536 total
Footnotes (2)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.
  • [F2]The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

Issuer

Fulcrum Therapeutics, Inc.

CIK 0001680581

Entity typeother

Related Parties

1
  • filerCIK 0001778843

Filing Metadata

Form type
4
Filed
May 28, 8:00 PM ET
Accepted
May 29, 4:15 PM ET
Size
8.8 KB